The story of Viagra presents a complex picture for investors. While the initial introduction generated significant gains, the end of its exclusive rights opened the floodgates to off-brand alternatives, dramatically https://techonpage.com/story7115047/the-copyright-and-big-pharma-a-volatile-bet